Stockscreener 앱 받기
41.46
1.20%
0.49
시간 외 거래:
41.46
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
Operating expenses (excl. COGS) of UroGen Pharma Ltd. – HAM:UR8 - TradingView
UroGen Pharma Ltd. Revenue Breakdown – HAM:UR8 - TradingView
Urogen Pharma Ltd (URGN) Institutional Confidence - TradingKey
Price to earnings forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
Price to earnings forward of UroGen Pharma Ltd. – FWB:UR8 - TradingView
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $42 - 富途牛牛
(URGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
URGN Maintained by Guggenheim -- Price Target Raised to $42 - GuruFocus
URGN stock trades steady as UroGen revenue grows and pipeline advances - Ad-hoc-news.de
What UroGen Pharma (URGN)'s UGN-501 IND Clearance Means For Shareholders - simplywall.st
Enterprise value to revenue forward of UroGen Pharma Ltd. – MUN:UR8 - TradingView
Price to sales forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
Price to sales forward of UroGen Pharma Ltd. – MUN:UR8 - TradingView
UroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow Moat (NASDAQ:URGN) - Seeking Alpha
Price to earnings forward of UroGen Pharma Ltd. – MUN:UR8 - TradingView
UroGen Pharma (URGN) AGM 2026 Summary - Quartr
What's Driving Investor Interest in UroGen Pharma (URGN) Ahead of Goldman Sachs - Kavout | AI
UroGen Pharma (URGN) Rallies On FDA Clearance As Valuation Questions Grow - simplywall.st
Urogen Pharma stock hits 52-week high at 41.45 USD By Investing.com - Investing.com South Africa
ETFs Investing in UroGen Pharma Ltd. Stocks - TradingView
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛
Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027 - Barchart.com
Urogen Pharma stock hits 52-week high at 41.45 USD - Investing.com
H.C. Wainwright reiterates UroGen Pharma stock rating on patent news - Investing.com UK
H.C. Wainwright reiterates UroGen Pharma stock rating on patent news By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
URGN Maintained by Oppenheimer -- Price Target Raised to $50 - GuruFocus
Oppenheimer Adjusts Price Target on UroGen Pharma to $50 From $40, Maintains Outperform Rating - marketscreener.com
Oppenheimer raises UroGen Pharma stock price target to $50 on sales outlook - Investing.com Canada
UroGen Pharma (URGN) Secures Patent Approval for Bladder Cancer Treatment - GuruFocus
Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Raises Target Price to $44 - 富途牛牛
UroGen receives US patent allowance for bladder cancer treatment - Investing.com UK
Should I Buy URGN (UroGen Pharma Ltd.) | AI Analysis, Technical & News Insights - Kavout | AI
UroGen receives US patent allowance for bladder cancer treatment By Investing.com - Investing.com Nigeria
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103 - The Manila Times
UroGen Receives New U.S. Patent Allowance Expected to - GlobeNewswire
UroGen patent allowance covers bladder cancer care without tumor resection - Stock Titan
URGN Stock Price, Quote & Chart - ChartMill
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer - BioBuzz
UroGen receives FDA clearance for bladder cancer trial By Investing.com - Investing.com Nigeria
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run - The Motley Fool
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run - The Motley Fool
UroGen Pharma (URGN) Is Up 5.8% After FDA Clears IND For UGN-501 Phase 1 Trial - Sahm
UroGen Pharma CMO Mark Schoenberg sells $400,000 in shares By Investing.com - Investing.com Australia
Form 4 Urogen Pharma Ltd For: 10 July By Investing.com - Investing.com India
UroGen Pharma CMO Mark Schoenberg sells $400,000 in shares - Investing.com
1.97%
0.83%
자본화:
|
볼륨(24시간):